Immunogenicity and safety of intradermal influenza vaccine in children

Vaccine

Volumn 29, Issue 44, 2011, Pages 7606-7610

  Esposito, Susanna ^a   Daleno, Cristina ^a   Picciolli, Irene ^a   Tagliaferri, Laura ^a   Scala, Alessia ^a   Prunotto, Giulia ^a   Montinaro, Valentina ^a   Galeone, Carlotta ^a,b   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Children; Influenza; Influenza vaccination; Intradermal influenza vaccine; Pediatrics

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; VACCINATION;

EID: 80053588703     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.021     Document Type: Article

References (23)

1. Esposito S., Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009, 22:244-249.
2. Centers for Disease Control and Prevention General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011, 60(RR-2):1-62.
3. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, 2:CD004879.
4. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hulquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
5. MedImmune LLC. FluMist Influenza Vaccine Live, Intranasal Spray; 2010-2011 Formula. Package insert.
6. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
7. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
8. Esposito S., Marchisio P., Ansaldi F., Bianchini S., Pacei M., Baggi E., et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010, 28:6137-6144.
9. Van Gelder V.W., Greenspan F.S., Dufresne N.E. Influenza vaccination: comparison of intracutaneous and subcutaneous methods. U S Nav Med Bull 1947, 47:197-206.
10. Centers for Disease Control and Prevention Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007, 56(RR-6):1-54.
11. Vankerckhoven V., Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opin Drug Deliv 2010, 7:1109-1125.
12. Falsey A.R. New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 2010, 28S:D24-D32.
13. Durando P., Iudici R., Alicino C., Alberti M., de Florentis D., Ansaldi F., et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011, 7(Suppl. 1):29-40.
14. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26:1525-1529.
15. Setti M., Fenoglio D., Ansaldi F., Filaci G., Bacilieri S., Sticchi L., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009, 27:3367-3372.
16. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E., et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78:440-445.
17. European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). London; March 12, 1997.
18. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
19. Esposito S., Marchisio P., Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008, 27(11 Suppl.):S149-S153.
20. Koutsonanos D.G., Del Pilar Martin M., Zarnitsyn V.G., Jacob J., Prausnitz M.R., Compans R.W., et al. Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis 2011, 204:582-591.
21. Chiu S.S., Peiris J.S.M., Chan K.H., Wong W.H.S., Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007, 119:1076-1082.
22. Sugimura T., Ito Y., Tananari Y., Ozaki Y., Maeno Y., Yamaoka T., et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008, 26:2700-2705.
23. Chiu S.S., Chan K.H., Tu W., Lau Y.L., Peiris J.S. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009, 27:4834-4839.